20. January 2019

Increased sales of AHIT® and urexent®

For AHIT® and urexent®, FBM-PHARMA has been able to increase its sales revenues in recent months due to targeted addressing of already active medical doctors. Furthermore, new medical practices have been added, which are currently receiving intensive support from FBM-PHARMA with regard to AHIT® and urexent®. Through these targeted measures, FBM-PHARMA hopes to be able to further increase sales revenues in the upcoming months.